A Phase 2 interventional study of Resiquimod in Warts, sponsored by Graceway Pharmaceuticals, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-02-19.
Sponsored by Graceway Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
A second purpose is to evaluate the safety of the drug.
184 studies on the registry are indexed under Warts; 29 are open to participants now.
This study's enrollment of 48 is below the median of 70 across 163 interventional studies indexed under Warts.
Browse Warts studies →Graceway Pharmaceuticals, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clearance of treated wart(s)
Partial clearance of treated wart(s)
This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resiquimod
Graceway Pharmaceuticals, LLC